The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
News|Articles|September 19, 2016
Adaptimmune Enters into Manufacturing Agreement with PCT
Author(s)Pharmaceutical Technology Editors
Adaptimmune entered into a manufacturing agreement with PCT for the manufacture of its SPEAR T-cell therapies.
Advertisement
On Sept. 19, 2016, Adaptimmune announced that it has entered into a strategic manufacturing agreement with PCT, a subsidiary of Caladrius Biosciences, for the supply of Adaptimmune’s SPEAR T-cell therapies. Under the terms of the agreement, Adaptimmume will benefit from exclusive access to an EU- and FDA-compliant manufacturing unit at PCT, the company said in a press announcement.
SPEAR T-cell therapies are novel cancer immunotherapies that use affinity T-cell receptors (TCR) to target and destroy cancer cells by strengthening patient’s natural T-cell response. Adaptimmune’s SPEAR T-cells are manufactured by isolating T-cells from the blood of cancer patients, transferring affinity enhanced TCRs, which have been modified to recognized cancer cells, into the cells; activating and expanding the T-cells; and, introducing the affinity enhanced cells back into the patient to enable the patient's immune system to attack cancer.
Source:
Advertisement
Related to this article
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
Advertisement
Advertisement